Exelixis, Inc. (0IJO.L)
USD 34.24
(-1.28%)
USD 34.24
(-1.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -73.05 Million USD | 76.51% |
| 2022 | -311.02 Million USD | 47.81% |
| 2021 | -595.89 Million USD | -120.6% |
| 2020 | -270.13 Million USD | -25.2% |
| 2019 | -215.76 Million USD | 28.7% |
| 2018 | -302.59 Million USD | -79.44% |
| 2017 | -168.63 Million USD | -550.46% |
| 2016 | 37.43 Million USD | -84.39% |
| 2015 | 239.8 Million USD | -14.74% |
| 2014 | 281.26 Million USD | 15.62% |
| 2013 | 243.25 Million USD | 46.84% |
| 2012 | 165.66 Million USD | 54.46% |
| 2011 | 107.25 Million USD | -3.39% |
| 2010 | 111.01 Million USD | 1646.43% |
| 2009 | -7.17 Million USD | 94.48% |
| 2008 | -130.01 Million USD | -832.5% |
| 2007 | -13.94 Million USD | -712.53% |
| 2006 | -1.71 Million USD | -103.28% |
| 2005 | 52.37 Million USD | -24.36% |
| 2004 | 69.25 Million USD | 9407.8% |
| 2003 | -744 Thousand USD | 92.97% |
| 2002 | -10.58 Million USD | -179.26% |
| 2001 | 13.35 Million USD | 390.29% |
| 2000 | -4.6 Million USD | -158.25% |
| 1999 | 7.9 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 40.5 Million USD | 169.72% |
| 2024 Q3 | -63.9 Million USD | -257.78% |
| 2024 Q1 | -58.09 Million USD | 20.47% |
| 2023 Q3 | -206 Million USD | 23.64% |
| 2023 FY | -73.05 Million USD | 76.51% |
| 2023 Q1 | -353.64 Million USD | -13.7% |
| 2023 Q2 | -269.78 Million USD | 23.71% |
| 2023 Q4 | -73.05 Million USD | 64.54% |
| 2022 Q3 | -515.44 Million USD | -10.62% |
| 2022 Q2 | -465.98 Million USD | 30.72% |
| 2022 FY | -311.02 Million USD | 47.81% |
| 2022 Q1 | -672.63 Million USD | -12.88% |
| 2022 Q4 | -311.02 Million USD | 39.66% |
| 2021 Q2 | -439.23 Million USD | -38.4% |
| 2021 Q1 | -317.37 Million USD | -17.49% |
| 2021 FY | -595.89 Million USD | -120.6% |
| 2021 Q4 | -595.89 Million USD | -15.69% |
| 2021 Q3 | -515.07 Million USD | -17.26% |
| 2020 Q4 | -270.13 Million USD | 5.69% |
| 2020 Q1 | -309.45 Million USD | -43.43% |
| 2020 Q2 | -478.8 Million USD | -54.73% |
| 2020 Q3 | -286.42 Million USD | 40.18% |
| 2020 FY | -270.13 Million USD | -25.2% |
| 2019 Q1 | -353.97 Million USD | -16.98% |
| 2019 FY | -215.76 Million USD | 28.7% |
| 2019 Q4 | -215.76 Million USD | 1.3% |
| 2019 Q3 | -218.61 Million USD | 37.04% |
| 2019 Q2 | -347.24 Million USD | 1.9% |
| 2018 Q4 | -302.59 Million USD | 11.26% |
| 2018 Q1 | -232.33 Million USD | -37.77% |
| 2018 Q3 | -341 Million USD | -49.72% |
| 2018 FY | -302.59 Million USD | -79.44% |
| 2018 Q2 | -227.76 Million USD | 1.97% |
| 2017 Q3 | -149.35 Million USD | -10.46% |
| 2017 Q4 | -168.63 Million USD | -12.91% |
| 2017 Q2 | -135.21 Million USD | -93.63% |
| 2017 Q1 | -69.83 Million USD | -286.53% |
| 2017 FY | -168.63 Million USD | -550.46% |
| 2016 Q2 | 266.22 Million USD | 138.18% |
| 2016 Q4 | 37.43 Million USD | -52.99% |
| 2016 Q1 | 111.77 Million USD | -53.39% |
| 2016 Q3 | 79.63 Million USD | -70.09% |
| 2016 FY | 37.43 Million USD | -84.39% |
| 2015 Q1 | 283.44 Million USD | 0.78% |
| 2015 FY | 239.8 Million USD | -14.74% |
| 2015 Q4 | 239.8 Million USD | 3.25% |
| 2015 Q3 | 232.24 Million USD | -24.91% |
| 2015 Q2 | 309.27 Million USD | 9.11% |
| 2014 Q1 | 185.48 Million USD | -23.75% |
| 2014 Q3 | 255.15 Million USD | 26.54% |
| 2014 Q2 | 201.63 Million USD | 8.71% |
| 2014 FY | 281.26 Million USD | 15.62% |
| 2014 Q4 | 281.26 Million USD | 10.23% |
| 2013 Q1 | 159.62 Million USD | -3.65% |
| 2013 Q4 | 243.25 Million USD | -2.53% |
| 2013 Q3 | 249.57 Million USD | 22.12% |
| 2013 Q2 | 204.36 Million USD | 28.03% |
| 2013 FY | 243.25 Million USD | 46.84% |
| 2012 Q2 | 114.55 Million USD | 2.65% |
| 2012 Q3 | 26.48 Million USD | -76.88% |
| 2012 FY | 165.66 Million USD | 54.46% |
| 2012 Q4 | 165.66 Million USD | 525.44% |
| 2012 Q1 | 111.59 Million USD | 4.05% |
| 2011 FY | 107.25 Million USD | -3.39% |
| 2011 Q3 | 143.74 Million USD | 6.39% |
| 2011 Q4 | 107.25 Million USD | -25.38% |
| 2011 Q2 | 135.11 Million USD | 2160.12% |
| 2011 Q1 | 5.97 Million USD | -94.62% |
| 2010 Q3 | 139.56 Million USD | 76.8% |
| 2010 Q1 | 18.07 Million USD | 351.83% |
| 2010 Q2 | 78.94 Million USD | 336.65% |
| 2010 Q4 | 111.01 Million USD | -20.46% |
| 2010 FY | 111.01 Million USD | 1646.43% |
| 2009 Q1 | -87.67 Million USD | 32.57% |
| 2009 Q2 | -42.81 Million USD | 51.16% |
| 2009 Q3 | -64.13 Million USD | -49.79% |
| 2009 Q4 | -7.17 Million USD | 88.81% |
| 2009 FY | -7.17 Million USD | 94.48% |
| 2008 Q1 | -4 Million USD | 71.3% |
| 2008 FY | -130.01 Million USD | -832.5% |
| 2008 Q4 | -130.01 Million USD | -319.82% |
| 2008 Q3 | 59.14 Million USD | 11.99% |
| 2008 Q2 | 52.81 Million USD | 1419.77% |
| 2007 Q1 | -24.68 Million USD | -1338.52% |
| 2007 Q4 | -13.94 Million USD | 51.85% |
| 2007 Q3 | -28.95 Million USD | -397.49% |
| 2007 FY | -13.94 Million USD | -712.53% |
| 2007 Q2 | 9.73 Million USD | 139.43% |
| 2006 Q4 | -1.71 Million USD | -103.02% |
| 2006 Q1 | 8.23 Million USD | -84.27% |
| 2006 Q3 | 56.79 Million USD | 97.0% |
| 2006 Q2 | 28.82 Million USD | 249.94% |
| 2006 FY | -1.71 Million USD | -103.28% |
| 2005 Q4 | 52.37 Million USD | -4.24% |
| 2005 Q1 | 81.63 Million USD | 17.88% |
| 2005 FY | 52.37 Million USD | -24.36% |
| 2005 Q3 | 54.7 Million USD | 28.85% |
| 2005 Q2 | 42.45 Million USD | -47.99% |
| 2004 FY | 69.25 Million USD | 9407.8% |
| 2004 Q1 | 27.15 Million USD | 3749.46% |
| 2004 Q2 | 68.05 Million USD | 150.66% |
| 2004 Q3 | 64.44 Million USD | -5.3% |
| 2004 Q4 | 69.25 Million USD | 7.45% |
| 2003 Q3 | 24.45 Million USD | 220.18% |
| 2003 FY | -744 Thousand USD | 92.97% |
| 2003 Q2 | 7.63 Million USD | 1156.25% |
| 2003 Q1 | 608 Thousand USD | 105.74% |
| 2003 Q4 | -744 Thousand USD | -103.04% |
| 2002 Q2 | 44.11 Million USD | 59.91% |
| 2002 FY | -10.58 Million USD | -179.26% |
| 2002 Q1 | 27.59 Million USD | 106.53% |
| 2002 Q3 | 20.5 Million USD | -53.52% |
| 2002 Q4 | -10.58 Million USD | -151.63% |
| 2001 Q1 | -26.97 Million USD | -486.07% |
| 2001 Q3 | 7.72 Million USD | 146.62% |
| 2001 Q4 | 13.35 Million USD | 72.95% |
| 2001 FY | 13.35 Million USD | 390.29% |
| 2001 Q2 | 3.13 Million USD | 111.61% |
| 2000 Q3 | -29.24 Million USD | 25.44% |
| 2000 Q4 | -4.6 Million USD | 84.26% |
| 2000 FY | -4.6 Million USD | -158.25% |
| 2000 Q1 | 777 Thousand USD | 0.0% |
| 2000 Q2 | -39.22 Million USD | -5147.62% |
| 1999 FY | 7.9 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 16.146% |
| Dynavax Technologies Corporation | 106.63 Million USD | 168.505% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -117.884% |
| Perrigo Company plc | 3.32 Billion USD | 102.199% |
| Illumina, Inc. | 1.21 Billion USD | 106.017% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.272% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 35.858% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.887% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.568% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 150.353% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -169.557% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1116.419% |
| Waters Corporation | 1.96 Billion USD | 103.726% |
| Biogen Inc. | 6.28 Billion USD | 101.162% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -928.873% |
| Evolus, Inc. | 63.7 Million USD | 214.664% |
| Adicet Bio, Inc. | -142 Million USD | 48.559% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -710.226% |
| bluebird bio, Inc. | 108.57 Million USD | 167.283% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 115.925% |
| FibroGen, Inc. | 56.76 Million USD | 228.684% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 106.38% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 1148.353% |
| Homology Medicines, Inc. | 18.43 Million USD | 496.214% |
| Geron Corporation | 14.76 Million USD | 594.885% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 104.608% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 136.882% |
| Myriad Genetics, Inc. | 88.1 Million USD | 182.917% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -34.639% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 34.427% |
| Zoetis Inc. | 4.76 Billion USD | 101.534% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -625.35% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 103.482% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 119.287% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.236% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -401.304% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 106.929% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 329.105% |
| Verastem, Inc. | -37.27 Million USD | -95.96% |
| Nektar Therapeutics | 210.24 Million USD | 134.746% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 63.442% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -98.484% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 107.544% |
| OPKO Health, Inc. | 230.68 Million USD | 131.667% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 141.201% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 46.049% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 51.63% |
| uniQure N.V. | -102.95 Million USD | 29.044% |
| Imunon, Inc. | -4.69 Million USD | -1454.496% |
| Blueprint Medicines Corporation | 702.83 Million USD | 110.394% |
| Insmed Incorporated | 721.62 Million USD | 110.123% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 105.29% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -134.007% |
| TG Therapeutics, Inc. | 17.86 Million USD | 508.969% |
| Incyte Corporation | -3.17 Billion USD | 97.699% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 109.539% |